A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes
Cell Death & Disease · 2023
DOI: 10.1038/s41419-023-05914-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Death & Disease, 2023. Verfasst von Wenli Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Public Research Center of Hainan Medical University, Hainan Medical University, Haikou, 570100, China. Hauptthemen laut MEDLINE: Neoplasms, T-Lymphocytes, Cytotoxic, Cancer Vaccines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite the great success of CTLA-4 blocking in cancer treatment, the use of anti-CTLA-4 monoclonal antibodies still faces many limitations. Now, immune checkpoint blocking coupled with adoptive cell therapy is gaining much attention. In this paper, we reported a strategy on the basis of anti-CTLA-4 nanobody (Nb)-modified liposomes to improve these obstacles. An Nb36/liposome complex was constructed and utilized as a blocker of the CTLA-4/B7 signal pathway in a combination with dendritic cell (DC)/tumor fusion vaccine to enhance the CD8 + T cell cytokine secretion, activation, proliferation, as well as specific cytotoxicity. Moreover, the CD8 + T cells induced by LPS-Nb36 and DC/tumor fusion vaccine led to higher CD8 + T cell effector function in vivo, which significantly retarded tumor growth and lengthened survival of tumor-bearing mice (HepG2, A549, and MGC-803). Our data demonstrate that the anti-CTLA-4 Nb-modified liposomes in connection with DC/tumor fusion vaccines enhance the CD8 + T cell antitumor activity in vitro and in vivo, and is expected to be an alternative therapy for patients with malignancies that have T cell dysfunction or have poor treatment against anti-CTLA-4 mAb.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Public Research Center of Hainan Medical University, Hainan Medical University, Haikou, 570100, China.
- Tumor Institute, The First Affiliated Hospital of Hainan Medical University, Haikou, 570102, China.
- Key Laboratory of Emergency and Trauma of Ministry of Education, Key Laboratory of Tropical Cardiovascular Diseases Research of Hainan Province, Hainan Women and Children's Medical Center, Hainan Medical University, Hai…
- Department of Anatomy, Zunyi Medical University, Zunyi, 563006, China.
- School of Traditional Chinese Medicine, Hainan Medical University, Haikou, 570100, China.
- Guangxi Key Laboratory of Nanobody Research, Guangxi Medical University, Nanning, 530021, China.
ORCID-Profile: Yanda Lu, Shaojiang Zheng, Wu Wang
Zitieren
APA
Yang, W., Pang, Y., Wang, X., Lai, Z., Lu, Y., Zheng, S., & Wang, W. (2023). A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes. Cell Death & Disease. https://doi.org/10.1038/s41419-023-05914-w
Vancouver
Yang W, Pang Y, Wang X, Lai Z, Lu Y, Zheng S, et al. A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes. Cell Death & Disease. 2023. doi:10.1038/s41419-023-05914-w
BibTeX
@article{Yang2023,
author = {Yang, Wenli and Pang, Yanyang and Wang, Xi and Lai, Zhiheng and Lu, Yanda and Zheng, Shaojiang and Wang, Wu},
title = {A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes},
journal = {Cell Death & Disease},
year = {2023},
doi = {10.1038/s41419-023-05914-w}
}
EUVIMED